E. Anthony , D.C. Gaffney ,A. Bond , M. Prentice , J. Wu , H.P. Soyer
Biologic agents have been subsidised on the pharmaceutical benefi ts scheme since 2003. We present fi ndings of a review of our experience with psoriasis patients being treated with biologic agents over the past fi ve years. Data was collected from both a public teaching hospital dermatology department and a private dermatology clinic both in South Brisbane. Together these represent a large proportion of psoriasis patients treated with biologic agents in Queensland. Ongoing monitoring and analysis allows reasons for non-compliance or non-attendance to be analysed and positive interventions made.
